Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Continued to advance the development of CLD-401 towards the clinic- Presented new CLD-401 data and in situ TCE platform advances at the ESMO Congress 2026- Received $1.2 million gross proceeds from at-the-market registered direct offering- Reduced general and administrative expenses by $1.0 milli…